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Abstract
Background Pre-operative weight loss has been consistently associated with increased post-operative morbidity. The study
aims to determine if pre-operative oral nutritional supplements (ONSs) with dietary advice reduce post-operative
complications.
Methods Single-blinded randomized controlled trial. People with colorectal cancer scheduled for surgery with pre-operative
weight loss >1 kg/3–6months were randomized by using stratiﬁed blocks (1:1 ratio) in six hospitals (1 November 2013–28
February 2015). Intervention group was given 250mL/day ONS (10.1 KJ and 0.096 g protein per mL) and dietary advice. Control
group received dietary advice alone. Oral nutritional supplements were administered from diagnosis to the day preceding sur-
gery. Research team was masked to group allocation. Primary outcome was patients with one or more surgical site infection
(SSI) or chest infection; secondary outcomes included percentage weight loss, total complications, and body composition mea-
surements. Intention-to-treat analysis was performed with both unadjusted and adjusted analyses. A sample size of 88 was
required.
Results Of 101 participants, (55 ONS, 46 controls) 97 had surgery. In intention-to-treat analysis, there were 21/45 (47%) pa-
tients with an infection—either an SSI or chest infection in the control group vs. 17/55 (30%) in the ONS group. The odds ratio
of a patient incurring either an SSI or chest infection was 0.532 (P = 0.135 conﬁdence interval 0.232 to 1.218) in the unadjusted
analysis and when adjusted for random differences at baseline (age, gender, percentage weight loss, and cancer staging) was
0.341 (P = 0.031, conﬁdence interval 0.128 to 0.909). Pre-operative percentage weight loss at the ﬁrst time point after random-
ization was 4.1% [interquartile range (IQR) 1.7–7.0] in ONS group vs. 6.7% (IQR 2.6–10.8) in controls (Mann–Whitney U P =
0.021) and post-operatively was 7.4% (IQR 4.3–10.0) in ONS group vs. 10.2% (IQR 5.1–18.5) in controls (P = 0.016).
Conclusions Compared with dietary advice alone, ONS resulted in patients having fewer infections and less weight loss fol-
lowing surgery for colorectal cancer. We have demonstrated that pre-operative oral nutritional supplementation can improve
clinical outcome in weight losing patients with colorectal cancer.
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Introduction
Internationally, in terms of annual incidence, colorectal can-
cer is the third most common cancer in men and the second
in women.1 Surgery, combined with either neo-adjuvant or
adjuvant chemotherapy and/or radiotherapy in selected pa-
tients, is the mainstay of curative treatment for colon and
rectal malignancies.2 Malnutrition and weight loss have long
been associated with an increased post-operative morbidity
and mortality.3–5 However, despite this, neither pre-operative
nutritional assessment nor nutritional screening is commonly
practiced or integrated into the care pathways for patients
with colorectal cancer.2
In pre-operative patients with colorectal cancer, the preva-
lence of malnutrition has been reported as 36.4% by using
subjective global assessment, whilst clinically signiﬁcant or
severe weight loss has been reported in 39%6 and any weight
loss in 47% of people with colorectal cancer.7 The combina-
tion of a low muscle mass and impaired physical function re-
ferred to as sarcopenia8 has been identiﬁed in 12% of people
with pre-operative colorectal cancer by using computed to-
mography to measure muscle mass and is associated with
older age, lower body mass index, and increased rate of
post-operative complications.9 A review of the literature on
sarcopenia in abdominal malignancy concluded that
sarcopenia is predictive of poorer clinical outcomes, in-
creased morbidity, and increased hospital length of stay
(LoS).10 Within an ‘enhanced recovery after surgery’ (ERAS)
programme for colorectal cancer, patients who were mal-
nourished were found to be at increased risk of post-
operative morbidity, delayed recovery of gastrointestinal
function, and prolonged hospital stay.11 Thus, there is consid-
erable evidence that pre-operative malnutrition and
sarcopenia are important prognostic factors for post-
operative complications.12 It is therefore reasonable to test
whether or not nutritional interventions can decrease post-
operative morbidity to improve clinical endpoints. Enhanced
recovery after surgery programmes is now widespread, and
patients with colorectal cancer are now cared for in their
homes for an increased length of time both pre-operatively
and post-operatively because admission is often on the day
of surgery and post-surgical time to discharge has been dras-
tically reduced.13 Decreased hospital LoS with ERAS
programmes places more emphasis on pre-operative and
post-operative supportive interventions that can be delivered
in individuals’ own homes.
Pre-operative nutritional interventions in gastrointestinal
surgery have been evaluated in a Cochrane review, which in-
cludes a number of studies on immune-enhancing nutrition,
oral nutritional supplements (ONSs), and parenteral nutri-
tion.14 Studies have demonstrated a reduction in post-
operative complications with the use of pre-operative
immune-enhancing nutrition.15 However, many of these stud-
ies include well-nourished patients, excluding those on neo-
adjuvant anticancer therapy, and were conducted prior to
the implementation of ERAS programmes.14 Studies that
have looked at nutritional supplements in all participants un-
dergoing colorectal surgery have demonstrated mixed
results.16,17
All trials of ONS compared with either standard care or di-
etary advice in those with colorectal cancer included a mix-
ture of well-nourished and malnourished participants.18 In
one trial in people with colorectal cancer, a subgroup analysis
of those who had lost weight demonstrated a reduction in
surgical site infections (SSIs) in the ONS group compared with
the controls.17 There is a paucity of evidence on ONS in peo-
ple who have lost weight diagnosed with colorectal cancer
during the pre-operative period, although it has been repeat-
edly demonstrated in the evidence base that there is an asso-
ciation between a poor pre-operative nutritional status and
poor clinical outcomes.
The aim of this study was to determine if pre-operative ONS
with dietary advice, compared with dietary advice only, can re-
duce post-operative infections in people prior to surgical re-
section for colorectal cancer who have previously lost weight.
Materials and Methods
In this multi-centre, single-blinded, randomized controlled
trial, we studied people with colorectal cancer who had lost
weight pre-operatively to determine the effectiveness of oral
nutritional supplementation. The protocol was amended af-
ter commencement to incorporate the comprehensive com-
plication index (CCI),19 an extension to the widely used
grading system of post-operative complications.20 The proto-
col (version 6 August 2013) is available at www.manchester.
ac.uk/research/sorrel.burden/publications.
Study participants
The sample was recruited from colorectal surgical clinics in six
hospitals in the northwest of England from 1 November 2013
to 28 February 2015. All hospitals had an ERAS protocol in co-
lorectal surgery in place.
Participants were recruited at colorectal clinics. Data col-
lection took place in the participant’s residence for baseline
and pre-operative time points and either on a hospital ward
or participant’s residence for the post-operative visit. At
baseline, the participants’ characteristics were recorded
along with nutritional status measurements. Baseline visits
occurred when the participants agreed to be in the study
within a couple of days of surgical teams, informing the par-
ticipants that they were suitable for an operation. Partici-
pants were included in the study if they had a primary
colorectal tumour, were over 18 years old, listed for radical
surgery, had capacity for informed consent, and reported
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unintentional weight loss over the previous 3–6months
(>1 kg). This weight loss was based on a subgroup analysis
from a previous trial that demonstrated in all participants
with colorectal cancer who had lost weight a signiﬁcant
reduction in wound infections in the group receiving ONS
compared with controls.17 Participants were excluded if they
were pregnant or had a pacemaker precluding the use of
bioelectrical impedance analysis (BIA), already on a similar
nutritional supplement, or had insulin dependent diabetes.
Ethical approval and trial registration
This study has been approved by the National Research Ethics
Service Committee Northwest (12/NW/0208) and been
performed in accordance with the ethical standards laid
down in the 1964 Declaration of Helsinki and its later amend-
ments. All study participants provided written informed
consent prior to inclusion. The trial was pre-registered
ISRCTN: NCT24668100.
Randomization
The participants were randomly allocated on a 1:1 ratio by
using blocks of two ensuring equal numbers in each group.
Allocation was stratiﬁed according to tumour site (rectal vs.
colon) and surgical approaches (open vs. laparoscopic). Four
lists of random numbers were produced by a statistician,
and an independent researcher set up the randomization
procedure for each of the strata. Sequentially numbered
opaque sealed envelopes were used, which allowed block
randomization sequence allocation to be implemented and
ensured sequence allocation concealment. The participants
were randomized to either dietary advice alone (control) or
ONS and dietary advice (intervention). Identiﬁcation and
recruitment of participants were undertaken by National
Institute Health Research cancer nurses or colorectal special-
ist nurses at each site. Randomization was undertaken after
participants consented prior to the baseline measurements.
Intervention
The intervention comprised oral supplementation (Fortisip
Compact®, 10.1 KJ, 0.096 g of protein per mL, Nutricia UK) at
a dose of 250mL daily. Supplements were started at the point
of allocation of an operation date. A minimum of 5 days pre-
operative treatment was given. A sealed box containing sufﬁ-
cient supplements for 7 days was left with the participants
randomized to the intervention for each week prior to the
planned operation date. A mixture of vanilla and strawberry
ﬂavours were provided. Dietary advice was given to all partic-
ipants in the form of a leaﬂet (see Supplementary Material),
which was left with the participant and which formed the
basis of a structured discussion with the research assistant
(DG), a nutritionist, at the baseline visit. The dietary advice
given aimed to increase energy and protein intake through
dietary means by increasing the amount of high fat, sugar,
and protein-rich foods in the diet. The leaﬂet also recom-
mended the use of dietary supplements high in energy and
protein that could be purchased from high street retailers.
All participants were advised of potential side effects of the
ONS and advised to discontinue the intervention if adverse
effects were experienced.
Controls
Following randomization, procedures for control group
participants were identical to those for the intervention
group. This group received the dietary leaﬂet and discussion
with the nutritionist, and for the purposes of blinding, control
participants were given sealed cardboard boxes of identical
weight and appearance as the ONS group at the time of
group allocation. These boxes contained bottled water in
125mL bottles. Thus, the same quantity of either bottled
water or ONS (14 bottles) was in each cardboard box. Similar
to the intervention group, further supplies of water in sealed
boxes were delivered as required up to 24 h prior to admis-
sion date for surgery. The research team was blind to the
intervention, but the participants were not.
Adherence
All participants were asked to keep a diary of the drinks they
consumed for each week prior to surgery after recruitment.
They were asked how much and how frequently they con-
sumed the drinks. This diary was then given back to the
researcher in a sealed envelope and was not opened until
the unblinding at the end of the trial.
Data collection
The participants were seen three times by the research assis-
tant (DG) (i) at baseline, (ii) 24–48 h pre-operatively, and (iii)
5–7 days post operatively. Nutritional status measurements
were recorded at each time point, and clinical outcomes were
recorded from Day 1 up to 30 days post operatively.
Outcomes
The primary outcome was patients with one or more chest or
SSI deﬁned by using the US Centre for Disease Control
deﬁnitions.21 Secondary outcome measures included post-
operative complications recorded prospectively from the par-
ticipants’ medical records using a standard classiﬁcation.20
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This classiﬁcation was used to determine the CCI.19 Hospital
LoS was recorded from the day of surgery until date of
discharge. The participants received a telephone interview
30 days after surgery, and any self-reported potential compli-
cations were recorded and followed up in the participants’
medical records, although primary care records were not
accessed due to permission restrictions.
Nutritional status measurements were recorded as
secondary outcomes. Weight was measured to the nearest
0.1 kg on calibrated scales (Seca 875 ﬂat scale) with shoes
removed. Height was measured by using a portable
stadiometer to the nearest 0.1 cm (Harpenden pocket
stadiometer Practical Metrology, Sussex, UK) with partici-
pants looking straight ahead and shoes removed. Height
and weight were required to calculate baseline body mass in-
dex, percentage weight loss, fat-free mass index (FFMI), and
fat mass index (FMI) so are not reported as standalone mea-
sures. To calculate percentage weight loss, the participants
were asked to recall their previous weight (3–6months
ago); this was used with actual weight recorded at all time
points to determine percentage weight loss. Percentage
weight loss is included as it is part of the criteria that is used
to deﬁne malnutrition22 and has universally been used as a
prognostic variable for predicting post-operative outcome.6
Handgrip strength was measured by using the non-dominant
hand (Takei 5001 Grip Dynamometer Analogue). Three mea-
surements were taken and the mean recorded. Bioelectrical
impedance analysis was measured (Bodystat 1500 machine,
Isle of Man, Bodystat Ltd) with participant being adequately
hydrated and in a supine position. Fat-free mass and fat mass
measured by BIA were standardized to FFMI and FMI by
dividing by height squared.23
The nutritional screening and assessment tools used were
(i) patient-generated subjective global assessment (PG-SGA)24
and (ii) the malnutrition universal screening tool,25 which
were completed during the baseline visit to the participant’s
home. Only PG-SGA was recorded at subsequent visits. Die-
tary intake was assessed at each time point by using 24 h
semi-structured dietary recall method which was self-
reported. For the dietary recall, the participants were asked
semi-structured questions on all food and drink eaten in the
previous day, including quantities of food consumed by using
household measures, volumes of ﬂuids, cooking methods, and
ingredients in any recipes. For the dietary recalls, food por-
tions were converted to grams and analysed by using
Microdiet (Version 2, Downlee Systems Limited, UK) to esti-
mate total energy and protein intakes. The energy and protein
content of the ONS consumed for the corresponding day from
the diaries was added to the nutrient content assessed by 24 h
recall for the pre-operative time point to estimate daily total
energy and protein intakes in the intervention group. Quality
of life data, anthropometric measurements, and data on ad-
herence to nutritional aspects of ERAS protocols are available
in the Supplementary Material.
Power and sample size
We calculated that 88 patients needed to complete the
trial (44 in each arm) to meet the number required to
detect a difference in infective complications (chest and
SSI deﬁned by CDC deﬁnitions21) using 80% power,
alpha = 0.05 (based on p1 = 0.26 and p2 = 0.54 on one-sided
signiﬁcance using χ2 test of equal proportions).17 We
allowed for 12% dropout or non-completion and recruited
101 patients.
Data analysis
Means and standard deviations are used to describe nor-
mally distributed interval data, and for non-normally distrib-
uted data, median and interquartile ranges (IQRs) are
displayed. Categorical data are displayed by using numbers
and percentages. Conﬁdence intervals (CIs) were calculated
for primary and secondary outcomes where appropriate.
To determine if there were any effects from random differ-
ences at baseline from prognostic variables, a logistic re-
gression model was used. The dependent variable was
infections, and the covariants were age, gender, baseline
percentage weight loss, and cancer staging. Adjusted and
unadjusted models were performed. Differences between
groups were determined by using independent Student’s
t-tests for normally distributed interval data, and for skewed
data, Mann–Whitney U-tests were performed. For dichoto-
mous variables, χ2 or Fisher’s exact tests were used. For
nominal data, Kruskal–Wallis test was used to determine
the differences between groups. Data were analysed by
using SPSS version 22.26 There were no interim stopping
guidelines for this trial.
Results
CONSORT diagram
We recruited and randomly allocated 101 patients, of whom
96 completed the trial. The CONSORT ﬂow diagram of the
participants through the trial is shown in Figure 1. One par-
ticipant withdrew consent from the control group prior to
the pre-operative visit. Participant characteristics and base-
line measurements are shown in Table 1. Overall, there
were more participants in the intervention group. At the
point of recruiting participants, if it was undecided if sur-
gery was open or laparoscopic, the default used was
open-surgery stratum for randomization. The two arms of
the trial were well matched with similar proportions of par-
ticipants within each stratum, site of cancer, and type of op-
eration (laparoscopic or open). Data were complete for the
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majority of baseline assessments, and missing data were
recorded (Table 1). The trial was discontinued when recruit-
ment numbers were sufﬁcient to meet the power equations
for both arms.
Primary outcome
The data on the primary outcome of infectious complications
on an intention-to-treat analysis are shown in Table 2. The
odds of a patient having a chest or an SSI in the ONS group
compared with the control group was 0.532 (P = 0.135, CI
0.232 to 1.218) with an unadjusted analysis. However, when
adjusted for random effects at baseline, the odds of a patient
in the ONS group compared with the controls of having an in-
fection (either chest or surgical site) was 0.341 (P = 0.031 CI
0.128 to 0.909). Each type of infection was evaluated and
shown in Table 3. A signiﬁcant difference was demonstrated
between the ONS group and controls for SSI (odds ratio
0.41, CI 0.16 to 1.00, χ2 P = 0.044) with a lower rate of SSI
in the intervention arm compared with the control (20 vs.
38%). However, there was no difference for chest infections
(Fisher’s exact P = 0.359).
Secondary outcomes
On intention to treat analysis for total complications, there
were no signiﬁcant differences demonstrated. A total of 48
participants had a complication: 23/55 (42%) in the inter-
vention group and 25/45 (56%) in the control group (χ2
P = 0.114). For complications graded I or II, there were
13/55 (24%) in the intervention group and 11/45 (24%) in
the control group, and for grades III to IVb, there were 9
(16%) and 10 (22%) complications in the ONS and control
groups, respectively. A total of ﬁve people died, one in
the ONS and four in the control (P> 0.05). The median
CCI score was 29.6 (IQR 20.9–47.3) and 29.6 (IQR 20.9–
43.3) for the intervention and the control groups, respec-
tively (Mann–Whitney U P = 0.984). Hospital LoS was re-
corded for 92 participants, and in the ONS group, the
median LoS was 7 days (IQR 4.0–10.5) and in the controls
group also 7 days (IQR 4.0–10.0; Mann–Whitney U P =
0.630). Multivariate analysis for complications and LoS are
included in the Supplementary Material but showed no dif-
ference between groups with regard to infections, although
unsurprisingly, there was a signiﬁcant effect from disease
staging (Table S13).
Figure 1 CONSORT ﬂow diagram.
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Nutritional status and body composition
Nutritional status measurements are shown in Table 4. There
was a signiﬁcant difference in the percentage of weight lost
between groups both pre-operatively (intervention 4.1% IQR
1.7–7.0 vs. controls 6.7% IQR 2.6–10, P = 0.021) and post-
operatively (intervention 7.4% IQR 4.3–10 vs. controls 10.2%
IQR 5.1–18.5, P = 0.016). However, there was no signiﬁcant dif-
ference observed for the other measures of nutritional status
recorded nor handgrip strength or PG-SGA (P> 0.05 in all
cases). The changes in measurements among baseline, pre-
operative, and post-operative time points for BIA are shown in
Table 5, and descriptive statistics for BIA with between-group
comparisons are in the supplementary material (Table S12).
There were no differences in BIA between groups at the pre-
operative or post-operative time points. However, for the
mean difference between the intervention and the control
from baseline to pre-operative time points for FFMI (ONS
group 0.345 kg/m2, IQR 3.241 to 0.160 vs. control group
0.100 kg/m2, 0.520 to 0.3150 Mann–Whitney U P = 0.008),
there was a signiﬁcant difference but not for FMI (ONS group
0.105 kg/m2, IQR 0.170 to 0.315 vs. control group
0.150 kg/m2 IQR 0.310 to 0.135 P = 0.083).
Dietary intake
Data for self-report energy and protein intake by using 24-h
recall are shown in Table 6.
Provision and adherence of ONS
Oral nutritional supplements were provided to the partici-
pants for a median of 8 days (IQR 5–15). Of the 53 partici-
pants in the intervention arm, 39 (74%) returned a diary
detailing their adherence to the ONS. For participants who
returned a diary, 29 (74%) participants managed all the sup-
plements (two cartons daily), 2 (5%) participants reported
that they managed one and a half cartons, 3 (8%) participants
reported that they managed one carton, 3 (8%) managed half
a carton, and 2 (5%) participants reported that they did not
consume any of the ONS. Intolerance of ONS was reported
by seven participants who did not manage to follow the
ONS regimen; these included nausea reported by four partic-
ipants, abdominal discomfort reported by three participants,
and diarrhoea reported by two (two participants reported
more than one intolerance symptoms). Thus, seven partici-
pants reported that they did not tolerate the supplements
due to unpalatability.
Blood loss and duration of operation were included as var-
iables at baseline but were missing in the majority of in-
stances in medical records, so therefore are not reported.
Table 1 Participants’ characteristics and baseline clinical details
Control Intervention
Dietary
advice only
ONS and
dietary advice
Randomization n=46 n=55
Age mean (SD) 68.9 (11.49) 70.5 (11.66)
Gender n (%)
Male 32 (70) 35 (64)
Female 14 (30) 20 (36)
Occupation n (%)
Professional 13 (28) 19 (35)
Skilled 16 (35) 19 (35)
Unskilled 14 (30) 12 (22)
Unemployed 0 (0) 2 (4)
Missing 3 (7) 3 (5)
Site of surgery n (%)
Colon 29 (63) 35 (64)
Rectum 17 (37) 20 (36)
Type of surgery n (%)
Laparoscopic 30 (65) 37 (67)
Open 16 (35) 18 (33)
Smoking status n (%)
Never 12 (26) 27 (49)
Ex smoker 21 (45) 18 (33)
Current 9 (20) 10 (18)
Missing 4 (9) 0 (0)
Body mass index
Mean (SD) 25.5 (4.54) 25.9 (4.8)
Missing 0
Percentage weight loss
Median (IQR) 6.8 (3.4–12.1) 4.90 (2.2–8.8)
Missing 0
MUST n (%)
0 13 (28) 28 (51)
1 16 (35) 13 (24)
2 14 (30) 9 (16)
3 1 (2) 1 (2)
4 0 (0) 4 (7)
Missing 0 2 (4)
Handgrip strength
mean (SD) 24.9 (9.3) 25.0 (10.6)
Missing 4 0
Patient-generated SGA
median (IQR) 9 (4–12) 6 (4–10)
Missing 0
Cancer staging n (%)
I 1 (2) 2 (4)
II 4 (9) 9 (16)
III 26 (56) 26 (47)
IV 12 (26) 11 (20)
Villous adenoma 1 (2) 1 (2)
Missing 1 (2) 4 (7)
Did not have surgery 2 (4) 2 (3)
Anaesthetic risk score n (%)
Normal health 5 (11) 2 (4)
Mild systemic disease 19 (41) 24 (44)
Severe systemic disease 8 (17) 7 (13)
Missing data 14 (30) 22 (40)
Neo-adjuvant treatment
Radiotherapy short course 11 (23) 15 (27)
Chemotherapy short course 6 (13) 7 (18)
Chemotherapy long course 2 (4) 3 (5)
Number of comorbidities n (%)
0 6 (13) 15 (27)
1 7 (15) 8 (15)
2 12 (26) 9 (16)
3 4 (9) 9 (16)
More than 4 8 (17) 8(15)
Missing 9 (20) 6 (11)
IQR, interquartile range;MUST, malnutrition universal screening tool;
ONS, oral nutritional supplement; SGA, subjective global assessment.
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Table 6 Dietary intake at each time point for energy and protein intakes, including additional nutrition from oral nutritional supplements at pre-op-
erative time point
Energy (KJ) Protein (g)
Median (IQR) Median (IQR)
Time point Control ONS P-value Control ONS P-value
n=participants
Baseline 6085(4743–7493) 6407 (4233–8193) 0.760 68 (48–83) 57 (41–76) 0.271
n=93
Pre-operative 6350 (4714–6350) 8120 (6490–9831) 0.001 63 (49–78) 79 (67–97) 0.018
n=70
Post-operative 4499 (3218–6416) 5302 (3973–7173) 0.282 46 (31–70) 60 (43–70) 0.181
n=89
IQR, interquartile range; ONS, oral nutritional supplement.
Mann–Whitney U-tests.
Table 2 Logistic regression showing adjusted and unadjusted analyses for primary outcome (patients with one or more infections either a chest or
surgical site) as dependent variable and independent variables age, gender, cancer staging, baseline percentage weight loss, and treatment group
Unadjusted odds ratio P-value 95% CI Adjusted odds ratio P-value 95% CI
Weight loss (%) 0.952 0.182 0.885 to 1.024 0.922 0.059 0.848 to 1.003
Age (years) 0.998 0.928 0.964 to 1.034 0.998 0.920 0.956 to 1.041
Gender 1.500 0.366 0.623 to 3.613 0.976 0.963 0.347 to 2.747
TNM staging
Stage 1 4.250 0.341 0.216 to 83.517 8.903 0.239 0.234 to 338.3
Stage 2 8.500 0.112 0.609 to 118.637 11.113 0.079 0.760 to 162.5
Stage 3 2.361 0.275 0.505 to 11.049 3.034 0.185 0.588 to 15.662
Stage 4 4.250 0.020 1.252 to14.427 5.223 0.013 1.420 to 19.220
Treatment group (ONS/control) 0.532 0.135 0.232 to 1.218 0.341 0.031 0.128 to 0.909
CI, conﬁdence interval; ONS, oral nutritional supplement; TNM, staging, tumour, nodal, metastases. Hosmer and Lemeshow test P=
0.792 for adjusted analysis.
Table 3 Intention to treat analysis for number of participants with chest, surgical site, or urinary tract infections
Control Intervention
n=45(%) 95% CI n=55(%) 95% CI P-value
Surgical site infection 17 (38) 25.1 to 52.4 11 (20) 11.6 to 32.4 a0.044
Chest infection 3 (7) 2.3 to 17.9 5 (9) 3.9 to 19.6 b0.359
Urinary tract infection 6 (13) 6.3 to 26.2 4 (7) 2.9 to 17.3 a0.315
CI, conﬁdence interval.
aχ2.
bFisher’s exact test.
Table 4 Nutritional status measurements and screening and assessment tools in control and intervention groups
24–48 h pre-operative 5–7 days post-operative
n Control ONS P-value n Control ONS P-value
Handgrip mean (SD) 70 25.0 (8.52) 25.2 (10.07) 0.723 70 23.2 (7.85) 24.9 (9.89) a0.394
Percentage weight loss median (IQR) 73 6.7 (2.6–10.8) 4.1 (1.7–7.0) 0.021 79 10.2 (5.1–18.5) 7.4 (4.3–10.0) b0.016
PG-SGA score median (IQR) 69 6.5 (3.0–9.7) 4.0 (2.0–9.0) 0.215 72 12.0 (8.0–15.0) 10.0 (6.5–13.5) b0.062
IQR, interquartile range; ONS, oral nutritional supplement; PG-SGA, patient-generated subjective global assessment.
aIndependent Student’s t-tests.
bMann–Whitney U-test.
Table 5 Changes in bioelectrical impedance analysis between baseline and measurements at pre-operative and post-operative time points
Difference between baseline and
pre-operative measurements (n=69)
Difference between baseline and
post-operative measurements (n=64)
Controls ONS P-value controls ONS P-value
Fat-free mass index kg/m2
median (IQR)
0.100
(0.520, 0.3150)
0.345
(3.241, 0.160)
0.008a 0.720
(0.190, 1.865)
0.080
(1.010, 0.960)
0.100
Fat mass index kg/m2
median (IQR)
0.150
(0.310, 0.135)
0.105
(0.170, 0.315)
0.083a 0.200
(0.220, 0.885)
0.410
(0.100, 1.090)
0.242
IQR, interquartile range; ONS, oral nutritional supplement.
aMann–Whitney U-test.
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Discussion
This is the ﬁrst single-blind randomized controlled trial of
pre-operative ONS based on standard nutritional recom-
mendations27 in people with colorectal cancer who have
lost weight. We demonstrate on intention-to-treat analysis
signiﬁcantly fewer infections in the ONS and dietary ad-
vice group compared with controls who received dietary
advice alone. Prior to surgery, the participants who re-
ceived ONS with dietary advice lost signiﬁcantly less
weight, and this difference was maintained post-
operatively. Percentage weight loss has long been
regarded as a prognostic indicator for post-operative mor-
bidity,28 and this study demonstrates that a nutritional
intervention is clearly linked to fewer post-operative infec-
tious complications. The primary outcome was participants
who incurred one or more infections (chest or surgical
site) post operative.
It is notable in the analysis of BIA data that the partici-
pants who lost weight had less of a difference in muscle
lost between baseline and pre-operative time points. This
suggests that when people with colorectal cancer lose
weight, they are losing fat-free mass. Fat-free mass is com-
monly used as a surrogate marker for skeletal muscle
mass.29 Reduction in skeletal muscle mass is linked to
sarcopenia, which is known to be associated with reduced
function and increased frailty in older people.28 This is im-
portant as sarcopenia has been consistently linked to a
poorer post-operative outcome and is also known to impact
negatively on other cancer therapies.30 Preventing weight
loss and subsequent skeletal muscle mass would therefore
seem to be a logical therapeutic strategy, especially given
that it can be achieved by using a relatively inexpensive nu-
tritional intervention that is easy to administer in the com-
munity pre-operatively.
The compliance rates for such an intervention in this trial
are more than acceptable with two-thirds of participants
managing more than 75% of the recommended dose. Most
participants who were randomized to the ONS were able to
consume some of the drink, and we recorded a 71% adher-
ence rate. This supports the argument that weight loss in
colorectal cancer during the perioperative period is prevent-
able, and the beneﬁts of increasing nutritional intake pre-
operatively are sustained throughout the perioperative
period.
Oral nutritional supplementation was effective at increas-
ing the nutritional intake of the participants randomized to
the intervention in relation to energy and protein. In this
study, we did not look at the micronutrient proﬁle of the par-
ticipants’ intake, although this may be important if subclinical
levels or deﬁciencies of vitamins and minerals are present
prior to surgery. The ONS used in this study contained a full
proﬁle of vitamins and minerals in amounts proportionate
to the macronutrient composition. So, it is unclear if it were
either macronutrients in ONS that are having a positive effect
or indeed the mixture of nutrients within the substrate.
Micronutrients have been shown to be important in the
perioperative period,31 and there are some vitamins and min-
erals which may be deﬁcient particularly in older people.32 It
is also of note that ONSs supplemented with immune-
enhancing agents administered pre-operatively have resulted
in a reduction in infections in patients with colorectal
cancer.33
People with colorectal cancer lose weight due to symp-
tom load, psychological distress, and adjuvant treatment
effects.34 Weight loss in the perioperative period inﬂuences
people’s lives during recovery and post-operative rehabilita-
tion.34 Other researchers have highlighted that nutritional
information is a priority for individuals and their families.35
In a recent study of body composition, only 5% of people
with colorectal cancer were found to be cachexic based
on measurements of fat-free mass pre-operatively, suggest-
ing that weight loss is a treatable consequence of colorectal
cancer.36 In this study, the participants recruited had lost
more than 1 kg of weight. This was based on a subgroup
analysis of a previous trial, which showed that all weight-
losing participants who were randomized to receive ONS
compared with controls had signiﬁcantly fewer wound
infections.
This is the ﬁrst single-blind trial that we are aware of
with ONS based on standard nutritional requirements in
people with colorectal cancer. Improvements to decrease
bias in future would be to double blind the trial so both
participants and researchers are unaware of the allocation.
Whilst this design was considered for this trial, it was not
possible to obtain a non-active drink packaged as a pla-
cebo. The initial power equations indicated that there
should be a 28% difference in chest and SSIs between
groups, although the actual difference was 21%. This is
most likely due to evolving practice in surgery-improving
perioperative management as there has been the introduc-
tion of ERAS programmes and also an increase in laparo-
scopic surgery, resulting in fewer complications
overall.37,38 Nutrition is a supportive therapy in surgical on-
cology, and studies evaluating supportive therapies are sub-
ject to confounding factors that include technological
developments and procedural alterations to the primary
therapy as well as patient variables. This trial was designed
to determine effectiveness and therefore recruited partici-
pants at the time point that was appropriate for each indi-
vidual within the care pathway. This meant that the
participants were given ONS for different lengths of time
pre-operatively. Future trials could standardize the length
of time participants received ONS but also account for
other confounders such as neo-adjuvant therapies by strat-
iﬁcation because these factors also inﬂuence pre-operative
management. Interestingly, the regression analysis showed
that disease staging had a signiﬁcant effect on infections
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and also on patients with one or more complications. This
would therefore be a factor to consider in future trials.
The limitations of the study include reliance on participant
recall to determine weight loss over 3–6months which may
be subject to bias. However, there is no reason to believe that
this potential source of bias was differentially distributed
across groups. There were also random differences in baseline
variables which included differences in percentage weight loss
and staging of disease, albeit these were adjusted for in the
analysis. Also, individuals were required to ﬁll in diaries to as-
sess adherence, again potentially subject to reporting bias. An
alternate method of determining adherence is to collect the
empty cartons, or it may be preferable to develop a medication
event monitoring system, although such systems are costly and
themselves have disadvantages.39 Dietary assessment was
undertaken by 24h recall which only allows dietary intake to
be assessed over a short period. However, a reasonable level
of validity has been demonstrated with trained nutritionists
and with the assessment of macronutrients.40 Technological
developments surrounding the use of smartphone applications
and user-friendly databases offer more options in future trials
to directly record dietary intake for nutritional analyses.
We aimed to collect data pre-operatively and post-
operatively, although the participants were reluctant in some
instances to see the researcher immediately pre-operatively,
possibly due to anxiety levels about impending surgery.
Likewise, some were reluctant post-operatively as they were
still recovering from surgery. This led to some missing data
at these time points. Future research may need to consider
dropout rates in the region of 20–25%. Alternative outcomes
which are part of routine care may be used to determine
nutritional status or body composition.36 This could include
the use of computed tomography for body composition and
using food diaries undertaken as part of ERAS programmes.
The ﬁndings of this RCT are encouraging in that we
demonstrate a reduction of post-operative infections by pre-
operative nutritional supplementation. This supports the use
of ONS in people who have lost weight prior to surgery for
colorectal cancer and concurs with other research promoting
pre-operative optimization or prehabilitation.41 Nutritional
optimization of people with colorectal cancer should start
with nutritional screening by using a validated screening
tool25 then implementing nutrition intervention into
pre-operative assessment protocols. The opportunities for
nutritional interventions should be recognized for patients
having neo-adjuvant treatments as their pre-operative dura-
tion is longer than for patients proceeding directly to surgery.
On the basis of this trial, it seems likely that ONS increases
energy and protein intakes, which results in less periopera-
tive weight loss and preservation of skeletal muscle mass,
resulting in a positive effect on clinical outcome in people
who were otherwise losing weight prior to surgery for colo-
rectal cancer.
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